Admetsys' FDA Breakthrough Designation Accelerates Arrival of Fully Autonomous Clinical Robotics in Hospital
Posted:
Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
Waystar has signed a definitive agreement to acquire Iodine Software, a $1.25 billion deal that seeks to empower healthcare payments with more AI capabilities.
Read more here.
Doctors will be able to prescribe a new treatment for people with inflammatory bowel disease (IBD), after the UK medicines watchdog approved guselkumab (Tremfya) for use on the NHS.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us